Tetrandrine
Phase 3Small molecule
Tetrandrine is one of 40 small molecule programs targeting Connective Tissue Disease. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
176 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Tetrandrine
PPeking University Third Hospital
Phase 3
Actos
TakedaPreclinical
Celexa
AbbViePreclinical
Voltaren
NovartisPreclinical
Cataflam
NovartisPreclinical
Plaquenil
Jazz PharmaceuticalsPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Velcade
SShilpa Grover, MD, MPH
Preclinical
Vancocin
HHikma Pharmaceuticals LLC
Preclinical
Disalcid
JJoslin Diabetes Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
COVID-192 trials
Connective Tissue Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tetrandrine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPeking University Third Hospital